Skip to main content
PMC home page
Protein & Cell logoLink to Protein & Cell
. 2012 Jan 10;2(12):997–1005. doi: 10.1007/s13238-011-1134-y

Structural vaccinology: structure-based design of influenza A virus hemagglutinin subtype-specific subunit vaccines

Chunling Xuan 1,2, Yi Shi 1, Jianxun Qi 1, Wei Zhang 1,2, Haixia Xiao 4, George F Gao 1,2,3,4,✉
PMCID: PMC4875251  PMID: 22231357

Abstract

There is a great need for new vaccine development against influenza A viruses due to the drawbacks of traditional vaccines that are mainly prepared using embryonated eggs. The main component of the current split influenza A virus vaccine is viral hemagglutinin (HA) which induces a strong antibody-mediated immune response. To develop a modern vaccine against influenza A viruses, the current research has been focused on the universal vaccines targeting viral M2, NP and HA proteins. Crystallographic studies have shown that HA forms a trimer embedded on the viral envelope surface, and each monomer consists of a globular head (HA1) and a “rod-like” stalk region (HA2), the latter being more conserved among different HA subtypes and being the primary target for universal vaccines. In this study, we rationally designed the HA head based on the crystal structure of the 2009-pandemic influenza A (H1N1) virus HA as a model, tested its immunogenicity in mice, solved its crystal structure and further examined its immunological characteristics. The results show that the HA globular head can be easily prepared by in vitro refolding in an E. coli expression system, which maintains its intact structure and allows for the stimulation of a strong immune response. Together with recent reports on some similar HA globular head preparations we conclude that structure-based rational design of the HA globular head can be used for subtype-specific vaccines against influenza viruses.

Keywords: influenza virus, subunit vaccine, hemagglutinin, structure, design

Footnotes

An erratum to this article can be found at http://dx.doi.org/10.1007/s13238-012-2030-9.

References

  1. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., Moriarty N.W., Read R.J., Sacchettini J.C., Sauter N.K., Terwilliger T.C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002;58:1948–1954. doi: 10.1107/S0907444902016657. [DOI] [PubMed] [Google Scholar]
  2. Beigel J.H., Farrar J., Han A.M., Hayden F.G., Hyer R., de Jong M. D., Lochindarat S., Nguyen T.K., Nguyen T.H., Tran T.H., the Writing Committee of the World Health Organization et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–1385. doi: 10.1056/NEJMra052211. [DOI] [PubMed] [Google Scholar]
  3. Belser J.A., Lu X., Maines T.R., Smith C., Li Y., Donis R.O., Katz J.M., Tumpey T.M. Pathogenesis of avian influenza (H7) virus infection in mice and ferrets: enhanced virulence of Eurasian H7N7 viruses isolated from humans. J Virol. 2007;81:11139–11147. doi: 10.1128/JVI.01235-07. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., Wittes J., Iacuzio D., Piedra P., Treanor J., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr. 2000;136:168–175. doi: 10.1016/S0022-3476(00)70097-7. [DOI] [PubMed] [Google Scholar]
  5. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., Lu X., Joyce J.G., Shiver J.W., Casimiro D.R., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A. 2010;107:13701–13706. doi: 10.1073/pnas.1007465107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Caton A.J., Brownlee G.G., Yewdell J.W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) Cell. 1982;31:417–427. doi: 10.1016/0092-8674(82)90135-0. [DOI] [PubMed] [Google Scholar]
  7. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F., Webster R.G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998;351:472–477. doi: 10.1016/S0140-6736(97)11212-0. [DOI] [PubMed] [Google Scholar]
  8. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr. 1994;50:760–763. doi: 10.1107/S0907444994003112. [DOI] [PubMed] [Google Scholar]
  9. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333:850–856. doi: 10.1126/science.1205669. [DOI] [PubMed] [Google Scholar]
  10. Das K., Aramini J.M., Ma L.C., Krug R.M., Arnold E. Structures of influenza A proteins and insights into antiviral drug targets. Nat Struct Mol Biol. 2010;17:530–538. doi: 10.1038/nsmb.1779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. DuBois R.M., Aguilar-Yañez J.M., Mendoza-Ochoa G.I., Oropeza-Almazán Y., Schultz-Cherry S., Alvarez M.M., White S.W., Russell C.J. The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure. J Virol. 2011;85:865–872. doi: 10.1128/JVI.01412-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. DuBois R.M., Aguilar-Yañez J.M., Mendoza-Ochoa G.I., Oropeza-Almazán Y., Schultz-Cherry S., Alvarez M.M., White S.W., Russell C.J. The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure. J Virol. 2011;85:865–872. doi: 10.1128/JVI.01412-10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324:246–251. doi: 10.1126/science.1171491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., Ophorst C., Cox F., Korse H.J., Brandenburg B., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333:843–850. doi: 10.1126/science.1204839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60:2126–2132. doi: 10.1107/S0907444904019158. [DOI] [PubMed] [Google Scholar]
  16. Fields B.N., Knipe D.M., Howley P.M. Fields virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. [Google Scholar]
  17. Furuya Y., Regner M., Lobigs M., Koskinen A., Müllbacher A., Alsharifi M. Effect of inactivation method on the crossprotective immunity induced by whole ‘killed’ influenza A viruses and commercial vaccine preparations. J Gen Virol. 2010;91:1450–1460. doi: 10.1099/vir.0.018168-0. [DOI] [PubMed] [Google Scholar]
  18. Gamblin S.J., Haire L.F., Russell R.J., Stevens D.J., Xiao B., Ha Y., Vasisht N., Steinhauer D.A., Daniels R.S., Elliot A., et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science. 2004;303:1838–1842. doi: 10.1126/science.1093155. [DOI] [PubMed] [Google Scholar]
  19. Guan Y., Vijaykrishna D., Bahl J., Zhu H., Wang J., Smith G.J. The emergence of pandemic influenza viruses. Protein Cell. 2010;1:9–13. doi: 10.1007/s13238-010-0008-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ha Y., Stevens D.J., Skehel J.J., Wiley D.C. H5 avian and H9 swine influenza virus haemagglutinin structures: possible origin of influenza subtypes. EMBO J. 2002;21:865–875. doi: 10.1093/emboj/21.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Igarashi M., Ito K., Yoshida R., Tomabechi D., Kida H., Takada A. Predicting the antigenic structure of the pandemic (H1N1) 2009 influenza virus hemagglutinin. PLoS One. 2010;5:e8553. doi: 10.1371/journal.pone.0008553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Khurana S., Larkin C., Verma S., Joshi M.B., Fontana J., Steven A.C., King L.R., Manischewitz J., McCormick W., Gupta R.K., et al. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine. 2011;29:5657–5665. doi: 10.1016/j.vaccine.2011.06.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., King L.R., Ross T.M., Golding H. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One. 2010;5:e11548. doi: 10.1371/journal.pone.0011548. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  24. Kilbourne E.D. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12:9–14. doi: 10.3201/eid1201.051254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kubo Y., Yokoyama M., Yoshii H., Mitani C., Tominaga C., Tanaka Y., Sato H., Yamamoto N. Inhibitory role of CXCR4 glycan in CD4-independent X4-tropic human immunodeficiency virus type 1 infection and its abrogation in CD4-dependent infection. J Gen Virol. 2007;88:3139–3144. doi: 10.1099/vir.0.83202-0. [DOI] [PubMed] [Google Scholar]
  26. Kurtz J., Manvell R.J., Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 1996;348:901–902. doi: 10.1016/S0140-6736(05)64783-6. [DOI] [PubMed] [Google Scholar]
  27. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: A program to check the stereochemical quality of protein structures. J Appl Cryst. 1993;26:283–291. doi: 10.1107/S0021889892009944. [DOI] [Google Scholar]
  28. Lin Y.P., Shaw M., Gregory V., Cameron K., Lim W., Klimov A., Subbarao K., Guan Y., Krauss S., Shortridge K., et al. Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad Sci U S A. 2000;97:9654–9658. doi: 10.1073/pnas.160270697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lipsitch M., Cohen T., Murray M., Levin B.R. Antiviral resistance and the control of pandemic influenza. PLoS Med. 2007;4:e15. doi: 10.1371/journal.pmed.0040015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Meijer A., Bosman A., van de Kamp E.E.H.M., Wilbrink B., Du Ry van Beest Holle M., Koopmans M. Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test. J Virol Methods. 2006;132:113–120. doi: 10.1016/j.jviromet.2005.10.001. [DOI] [PubMed] [Google Scholar]
  31. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53:240–255. doi: 10.1107/S0907444996012255. [DOI] [PubMed] [Google Scholar]
  32. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459:931–939. doi: 10.1038/nature08157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326. doi: 10.1016/S0076-6879(97)76066-X. [DOI] [PubMed] [Google Scholar]
  34. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr. 2001;57:1373–1382. doi: 10.1107/S0907444901012471. [DOI] [PubMed] [Google Scholar]
  35. Russell R.J., Gamblin S.J., Haire L.F., Stevens D.J., Xiao B., Ha Y., Skehel J.J. H1 and H7 influenza haemagglutinin structures extend a structural classification of haemagglutinin subtypes. Virology. 2004;325:287–296. doi: 10.1016/j.virol.2004.04.040. [DOI] [PubMed] [Google Scholar]
  36. Russell R.J., Kerry P.S., Stevens D.J., Steinhauer D.A., Martin S. R., Gamblin S.J., Skehel J.J. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008;105:17736–17741. doi: 10.1073/pnas.0807142105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem. 2000;69:531–569. doi: 10.1146/annurev.biochem.69.1.531. [DOI] [PubMed] [Google Scholar]
  38. Stevens J., Blixt O., Tumpey T.M., Taubenberger J.K., Paulson J. C., Wilson I.A. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006;312:404–410. doi: 10.1126/science.1124513. [DOI] [PubMed] [Google Scholar]
  39. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., et al. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 1998;279:393–396. doi: 10.1126/science.279.5349.393. [DOI] [PubMed] [Google Scholar]
  40. Sun Y., Shi Y., Zhang W., Li Q., Liu D., Vavricka C., Yan J., Gao G.F. In silico characterization of the functional and structural modules of the hemagglutinin protein from the swineorigin influenza virus A (H1N1)-2009. Sci China Life Sci. 2010;53:633–642. doi: 10.1007/s11427-010-4010-8. [DOI] [PubMed] [Google Scholar]
  41. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., Pham T.S., Vo C.D., Le T.Q., Ngo T.T., the World Health Organization International Avian Influenza Investigative Team et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med. 2004;350:1179–1188. doi: 10.1056/NEJMoa040419. [DOI] [PubMed] [Google Scholar]
  42. Vavricka C.J., Li Q., Wu Y., Qi J., Wang M., Liu Y., Gao F., Liu J., Feng E., He J., et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011;7:e1002249. doi: 10.1371/journal.ppat.1002249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Vitale F., Russo Alesi D., Bonura F., Di Benedetto M.A., Mammina C., Romano N. Change in size of the envelope glycoprotein of a human immunodeficiency virus 1 (HIV 1) strain. Microbiologica. 1991;14:15–20. [PubMed] [Google Scholar]
  44. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., Wilson I.A., García-Sastre A., Moran T.M., Palese P. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A. 2010;107:18979–18984. doi: 10.1073/pnas.1013387107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature. 1981;289:366–373. doi: 10.1038/289366a0. [DOI] [PubMed] [Google Scholar]
  46. Wood J.M., Robertson J.S. From lethal virus to lifesaving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol. 2004;2:842–847. doi: 10.1038/nrmicro979. [DOI] [PubMed] [Google Scholar]
  47. Xu R., McBride R., Paulson J.C., Basler C.F., Wilson I.A. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol. 2010;84:1715–1721. doi: 10.1128/JVI.02162-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Yang Y., Sugimoto J.D., Halloran M.E., Basta N.E., Chao D.L., Matrajt L., Potter G., Kenah E., Longini I.M., Jr. The transmissibility and control of pandemic influenza A (H1N1) virus. Science. 2009;326:729–733. doi: 10.1126/science.1177373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zhang W., Qi J., Shi Y., Li Q., Gao F., Sun Y., Lu X., Lu Q., Vavricka C.J., Liu D., et al. Crystal structure of the swine-origin A (H1N1)-2009 influenza A virus hemagglutinin (HA) reveals similar antigenicity to that of the 1918 pandemic virus. Protein Cell. 2010;1:459–467. doi: 10.1007/s13238-010-0059-1. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES